Document is current
Any future updates will be listed below
-
Authors
Aldayel, Abdulaziz M.
Bosaeed, Mohammad
Almansour, Sarah
Alharbi, Naif Khalaf
Alenazi, Mohammed
Aljami, Haya A.
Aldibasi, Omar
Aljouie, Abdulrhman
Xu, Haiyue
Cui, Zhengrong
-
Funding
Funding for this research was provided by:
King Abdullah International Medical Research Center (R798/RC18/272 to A.M.A, NRC23R/565/08 to A.M.A)
National Institutes of Health (CA135274 to Z.C.)
University of Texas at Austin (Alfred and Dorothy Mannino Fellowship in Pharmacy at UT Austin (to Z.C))
- License Information
-
More Information
Article History
Received: 5 May 2024
Accepted: 10 February 2025
First Online: 28 March 2025
Declarations
:
: All procedures and methods involving animals were approved by the Institutional Animal Care and Use Committee at The University of Texas at Austin (AUP-2015–00080 and -00189). The authors confirm that all of the methods were carried out in accordance with the relevant guidelines and regulations at The University of Texas at Austin. The clinical portion of this study was approved by the Institutional Review Board of the King Abdulaziz Medical City (KAMC), which reviewed and approved the study (N. NRC22R/042/01) under the ethical standards of the responsible committees on human experimentation and the Declaration of Helsinki. Informed consent was obtained for participation in this study.
: The authors declare the following patent application: Cui, Z and Aldayel, AM. Selectively cleavable therapeutic nanoparticles, Board of Regents, US patent application, No: US20210386680A1, 62/776,005, international patient application number PCT/US2019/064840.
